Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Free Report) have been given an average rating of “Moderate Buy” by the eight analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $35.71.
Several research firms have recently weighed in on DAWN. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, July 30th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, August 1st. Bank of America raised Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and boosted their price objective for the company from $11.00 to $24.00 in a research note on Thursday, August 1st. Piper Sandler reaffirmed an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, July 8th. Finally, Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, July 25th.
View Our Latest Report on Day One Biopharmaceuticals
Insider Buying and Selling
Institutional Investors Weigh In On Day One Biopharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Arizona State Retirement System lifted its position in shares of Day One Biopharmaceuticals by 8.2% during the fourth quarter. Arizona State Retirement System now owns 13,373 shares of the company’s stock worth $195,000 after acquiring an additional 1,010 shares in the last quarter. Handelsbanken Fonder AB bought a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at $254,000. New York State Common Retirement Fund lifted its holdings in Day One Biopharmaceuticals by 20.5% during the 4th quarter. New York State Common Retirement Fund now owns 78,299 shares of the company’s stock worth $1,143,000 after purchasing an additional 13,294 shares in the last quarter. Fisher Asset Management LLC boosted its stake in Day One Biopharmaceuticals by 88.9% in the 4th quarter. Fisher Asset Management LLC now owns 68,411 shares of the company’s stock worth $999,000 after purchasing an additional 32,203 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Day One Biopharmaceuticals by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 452,934 shares of the company’s stock valued at $6,613,000 after buying an additional 5,796 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors.
Day One Biopharmaceuticals Stock Performance
Shares of NASDAQ:DAWN opened at $14.09 on Tuesday. Day One Biopharmaceuticals has a 52-week low of $9.67 and a 52-week high of $18.07. The company has a market capitalization of $1.23 billion, a PE ratio of -5.61 and a beta of -1.51. The company has a fifty day moving average of $14.07 and a 200-day moving average of $14.79.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report) last posted its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.70. The business had revenue of $8.19 million for the quarter, compared to the consensus estimate of $0.90 million. On average, equities analysts forecast that Day One Biopharmaceuticals will post -2.29 EPS for the current fiscal year.
Day One Biopharmaceuticals Company Profile
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Further Reading
- Five stocks we like better than Day One Biopharmaceuticals
- 3 Monster Growth Stocks to Buy Now
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- How to Calculate Return on Investment (ROI)
- 2 Option Strategies to Maximize Profits in a Bear Market
- How to buy stock: A step-by-step guide for beginners
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.